The FDA put a hold on Bright Minds Biosciences' new drug for kids with epilepsy, causing shares to fall 55%.

DRUG · Bright Minds Biosciences Inc.

The AI's read

The pause can delay the U.S. study as Bright Minds responds to the FDA’s safety questions. Other studies continue, and earlier results in adults were encouraging. But the FDA wants more information, and Bright Minds cannot say whether or when the hold will end.